CyBio and STRATEC sign sales cooperation agreement

1/25/2006, 2:35 PM (Source: GlobeNewswire)


Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- STRATEC expands its shareholding in CyBio

Jena / Birkenfeld, January 25th, 2006

On January 23th, 2006, CyBio AG, Jena, and STRATEC Biomedical Systems
AG, Birkenfeld, signed a cooperation agreement at "LabAutomation",
one of the most important laboratory automation fairs, in Palm
Springs, California, USA. The object of this contractual agreement is
the non-exclusive sale by CyBio of systems of STRATEC's "Robion"
brand. These systems are being designed and manufactured by STRATEC
for the pharmaceutical and biotechnology sector and will be sold
worldwide by CyBio under its own name.

The fully automated systems designed and manufactured by STRATEC will
initially supplement CyBio's liquid handling portfolio with a
flexible pipetting platform, thus expanding CyBio's range of
applications for the life science industry. This cooperation will
enable STRATEC to benefit from CyBio's established global sales
network and will thus save it from having to build up its own costly
sales organization.

In view of this development, on January 20th, 2006 STRATEC Biomedical
Systems AG increased its existing shareholding in its new sales
partner, CyBio, by 6.250% from 4.875% to 11.125% by means of an
off-market transfer placement.
About CyBio
CyBio AG (; ISIN: DE0005412308), with its
principal headquarters in Jena, Germany, and sales subsidiaries in
Europe and the USA, is a globally active life science company. As an
innovative technology company, CyBio develops, produces and sells
technology platforms used in drug discovery.
With more than 15 years of experience, CyBio's hardware, software and
service products have set new standards in terms of their precision,
speed and engineering output in the field of automated drug
The product portfolio consists of a wide range of pharmaceutical and
agrochemical research solutions: liquid handling, detection, software
and system integration, in order to create fully automated screening
technologies holding the key to innovative and efficient
high-throughput drug discovery.
STRATEC Biomedical Systems AG (
designs and manufactures fully automated systems for its partners in
the fields of clinical diagnostics and biotechnology. These partners
market such systems, in general together with their own reagents, to
laboratories and research institutes around the world. The company
develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime
Standard segment of the Frankfurt Stock Exchange, in the Gate-M
trading segment of the Stuttgart Stock Exchange and on other

The STRATEC Group comprises the listed holding company "STRATEC
Biomedical Systems AG", as well as the wholly-owned subsidiaries
"STRATEC NewGen GmbH" and "Robion AG".
For further information please contact:

CyBio AG
Franziska Haase, Investor Relations
Göschwitzer Strasse 40,
07745 Jena
Phone: +49 (0)3641 351 401
Fax: +49 (0)3641 351 409

STRATEC Biomedical Systems AG
André Loy, Investor
Gewerbestrasse 37, 75217 Birkenfeld
Phone: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
--- End of Message ---
WKN: 541230; ISIN: DE0005412308; Index: CDAX;
Listed: General Standard in Frankfurter Wertpapierbörse, Geregelter
Markt in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover;
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.